LIFECORE BIOMEDICAL, INC. \DE\
For the period ended Feb 23, 2025. Filed Apr 3, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Feb 23, 2025 · Filed Apr 3, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Income or loss per share
- Income or loss per share
The following table sets forth the weighted average shares used in the computation of basic and diluted income or loss per share:
| Three months ended | Nine months ended | |||
|---|---|---|---|---|
| February 23, 2025 | February 25, 2024 | February 23, 2025 | February 25, 2024 | |
| Weighted average shares for basic income or loss per share | 37,020,570 | 30,487,596 | 34,080,062 | 30,449,673 |
| Redeemable convertible preferred stock | — | 5,899,388 | — | 5,791,809 |
| Stock options, RSUs and PSUs | — | 221,920 | — | 227,389 |
| Weighted average shares for diluted income or loss per share | 37,020,570 | 36,608,904 | 34,080,062 | 36,468,871 |
Due to the Company’s net loss for the three and nine months ended February 23, 2025, the diluted income or loss per share is calculated using only the basic weighted average common shares outstanding and thus excludes the following securities on an as-converted basis as of February 23, 2025.
| February 23,2025 | |
|---|---|
| Redeemable Convertible Preferred Stock | 6,875,074 |
| Stock options | 1,418,355 |
| Restricted stock units | 1,531,850 |
| Performance share units | 2,175,000 |
| Total | 12,000,279 |
See note 11 for more information about Series A Redeemable Convertible Preferred Stock and note 13 for more information about stock options, restricted stock units and performance share units.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.